Lead-212 PSV359 Therapy for Patients With Solid Tumors

ConditionsPancreatic Ductal Adenocarcinoma Gastric Cancer Esophageal Cancer Colorectal Cancer Ovarian Cancer Head and Neck Cancer Sarcoma Mesothelioma

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age18-90

SponsorPerspective Therapeutics

About this trial

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Eligibility criteria

Qualifiers

Aged ≥ 18 years

Satisfactory organ function as determined by laboratory testing

Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1

Life expectancy > 3 months

Disqualifiers

Known hypersensitivity to the active agent or any of the excipients

Active secondary malignancy

Pregnancy or breastfeeding a child

Known brain metastases

Trial design

Treatments tested in this trial

[203Pb]Pb-PSV359
[212Pb]Pb-PSV359

Treatment groups

112 Participants

are divided into 2 treatment groups

Locations

Florida

Biogenix33165, Miami United States

University of Miami33125, Miami United States

Kentucky

University of Kentucky40536, Lexington United States

Missouri

Saint Louis University63110, St Louis United States

Sponsors and collaborators

Perspective Therapeutics

Lead sponsor

Source ClinicalTrials.gov